2062200-97-7
Chemical Structure
XL413 monohydrochloride
Synonym(s): BMS-863233 monohydrochloride
- CAS No.: 2062200-97-7
- Formula:C14H13Cl2N3O2
- Molecular Weight:326.18
IUPAC Name: (S)-8-chloro-2-(pyrrolidin-2-yl)benzofuro[3,2-d]pyrimidin-4(3H)-one hydrochloride
InChIKey: UNDKJUKLBNARIZ-FVGYRXGTSA-N
SMILES: O=C1C(OC2=CC=C(Cl)C=C23)=C3N=C([C@H]4NCCC4)N1.[H]Cl
Biological Activity: XL413 monohydrochloride (BMS-863233 monohydrochloride) is an orally active, ATP-competitive, selective CDC7 kinase inhibitor. XL413 monohydrochloride reduces MCM2 phosphorylation levels, decreases DNA replication origin activation, and inhibits CD69 upregulation in stimulated lymphocytes. XL-413 possesses cell-dependent antiproliferative and pro-apoptotic activities. XL413 monohydrochloride attenuates ATR inhibitor-induced excessive origin activation, altered replication fork speed, and antiproliferative effects in sensitive cancer cells. XL413 monohydrochloride inhibits SARS-CoV-2 infection. XL413 monohydrochloride can be used for research related to cancer and SARS-CoV-2 infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
XL413 monohydrochloride | 99.65% | XL413 monohydrochloride (BMS-863233 monohydrochloride) is an orally active, ATP-competitive, selective CDC7 kinase inhibitor. XL413 monohydrochloride reduces MCM2 phosphorylation levels, decreases DNA replication origin activation, and inhibits CD69 upregulation in stimulated lymphocytes. XL-413 possesses cell-dependent antiproliferative and pro-apoptotic activities. XL413 monohydrochloride attenuates ATR inhibitor-induced excessive origin activation, altered replication fork speed, and antiproliferative effects in sensitive cancer cells. XL413 monohydrochloride inhibits SARS-CoV-2 infection. XL413 monohydrochloride can be used for research related to cancer and SARS-CoV-2 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lumeau A, et al. High levels of DNA replication initiation factors indicate ATRi sensitivity via excessive origin firing[EB/OL]. bioRxiv, 2025.
- [2]. Liu X, et al. SARS-CoV-2-host proteome interactions for antiviral drug discovery. Molecular systems biology. 2021 Nov;17(11):e10396. [Content Brief]
- [3]. Chen EW, et al. A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation. Frontiers in immunology. 2019;10:1718. [Content Brief]
- [4]. Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300. [Content Brief]
